• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Solanezumab for Alzheimer’s: the truth is still out there

05.12.2016/in News /by X7 Research

Alzheimer’s Association estimates that 46 billion people worldwide are affected by this disease, with the financial burden of Alzheimer’s reaching 604 billion USD per year worldwide. Nature journal predicts the prevalence of the disease will reach 130 million by the year 2050. The pharmaceutical industry and multiple governments are struggling to find the cure, and this struggle is far from victory.

Solanezumab (Eli Lilly, USA) is a monoclonal antibody that targets b-amyloid, a protein which builds up into subcortical plaques in brain tissue of affected individuals. This protein is presumed to be involved in neuronal death which results in a typical clinical representation of Alzheimer’s disease.

In 2014, Eli Lilly confirmed the drug to be ineffective in the treatment of mild to moderate Alzheimer’s per the results of EXPEDITION 1 and EXPEDITION 2 randomized multicenter trials. The company had not given up then and conducted a new trial – EXPEDITION 3 was designed to investigate the efficacy of solanezumab in the treatment of mild Alzheimer’s only, and 2100 patients were included in this study.

A year ago, the company released preliminary study results, per which the drug was going to be proven effective. Unfortunately, final study results were disappointing, and on November 23rd this year Eli Lilly published an official press release confirming that treatment with solanezumab didn’t improve ADAS-Cog14 score (primary endpoint of the study) compared to placebo (p = 0,95).

Yet, The company has not lost its faith in solanezumab because Alzheimer’s is probably should be treated earlier. Eli Lilly still relies on solanezumab in A4 trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s). People aged 65-85 years without signs of the disease but with evidence of b-amyloid accumulation in brain tissue on PET scans are included in this study.

 

Sources:

  1. https://investor.lilly.com/releasedetail.cfm?ReleaseID=1000871
  2. http://www.nejm.org/doi/10.1056/NEJMoa1312889
  3. http://www.nature.com/news/how-to-defeat-dementia-1.20949
  4. https://clinicaltrials.gov/ct2/show/NCT02008357
  5. http://a4study.org/about/
  6. http://www.alz.org/global
Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 6 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
EMA releases draft guidance on risk management in first-in-human clinical t... Acceptance of results of clinical trials conducted in Russia for registration...
Scroll to top